These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1737087)

  • 1. Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice.
    Voncken JW; Morris C; Pattengale P; Dennert G; Kikly C; Groffen J; Heisterkamp N
    Blood; 1992 Feb; 79(4):1029-36. PubMed ID: 1737087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ph-positive leukemia: a transgenic mouse model.
    Groffen J; Voncken JW; Kaartinen V; Morris C; Heisterkamp N
    Leuk Lymphoma; 1993; 11 Suppl 1():19-24. PubMed ID: 8251894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice.
    Heisterkamp N; Voncken JW; Senadheera D; Hemmeryckx B; Gonzalez-Gomez I; Reichert A; Pattengale PK; Groffen J
    Int J Mol Med; 2001 Apr; 7(4):351-7. PubMed ID: 11254872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
    Voncken JW; Kaartinen V; Pattengale PK; Germeraad WT; Groffen J; Heisterkamp N
    Blood; 1995 Dec; 86(12):4603-11. PubMed ID: 8541551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
    Brain J; Saksena A; Laneuville P
    Leuk Res; 2002 Nov; 26(11):1011-6. PubMed ID: 12363470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.
    Heisterkamp N; Voncken JW; Senadheera D; Gonzalez-Gomez I; Reichert A; Haataja L; Reinikainen A; Pattengale PK; Groffen J
    Blood; 2000 Sep; 96(6):2226-32. PubMed ID: 10979970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetic characterization of a BCR-ABL transduced mouse cell line.
    Rudolph C; Hegazy AN; von Neuhoff N; Steinemann D; Schröck E; Stripecke R; Klein C; Schlegelberger B
    Cancer Genet Cytogenet; 2005 Aug; 161(1):51-6. PubMed ID: 16080957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
    Mishra S; Zhang B; Groffen J; Heisterkamp N
    Leukemia; 2004 Jan; 18(1):23-8. PubMed ID: 14603339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal characteristics of acute lymphoblastic cells derived from BCR/ABL p190 transgenic mice.
    Griffiths SD; Healy LE; Ford AM; Bennett CA; Voncken JW; Heisterkamp N; Groffen J; Greaves MF
    Oncogene; 1992 Jul; 7(7):1391-9. PubMed ID: 1377812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
    Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
    Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.
    Kaur P; Feldhahn N; Zhang B; Trageser D; Müschen M; Pertz V; Groffen J; Heisterkamp N
    Mol Cancer; 2007 Oct; 6():67. PubMed ID: 17958915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector.
    Uchida N; Hanawa H; Dan K; Inokuchi K; Shimada T
    J Nippon Med Sch; 2009 Jun; 76(3):134-47. PubMed ID: 19602820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
    Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product.
    Castellanos A; Pintado B; Weruaga E; Arévalo R; López A; Orfao A; Sánchez-García I
    Blood; 1997 Sep; 90(6):2168-74. PubMed ID: 9310467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a cell line with variant BCR/ABL breakpoint expressing P180BCR/ABL from late-appearing Philadelphia-positive acute biphenotypic leukemia.
    Inokuchi K; Shinohara T; Futaki M; Hanawa H; Tanosaki S; Yamaguchi H; Nomura T; Dan K
    Genes Chromosomes Cancer; 1998 Nov; 23(3):227-38. PubMed ID: 9790503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone.
    Winter SS; Greene JM; McConnell TS; Willman CL
    Leukemia; 1999 Dec; 13(12):2007-11. PubMed ID: 10602422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restricted oncogenicity of BCR/ABL p190 in transgenic mice.
    Voncken JW; Griffiths S; Greaves MF; Pattengale PK; Heisterkamp N; Groffen J
    Cancer Res; 1992 Aug; 52(16):4534-9. PubMed ID: 1643646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.